Lyell Immunopharma (LYEL) Other Gross PP&E Adjustments (2020 - 2026)
Lyell Immunopharma recorded quarterly Other Gross PP&E Adjustments of -$17.8 million in Q1 2026, down 121.67% quarter-over-quarter from $82.3 million in Q4 2025, and up 24.36% year-over-year from -$14.3 million in Q1 2025.
Lyell Immunopharma's Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at -$17.8 million for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments rose 24.36% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$17.8 million (up 24.36% YoY), while the FY2025 annual figure was $82.3 million, down 2.16% from the prior year.
- Other Gross PP&E Adjustments came in at -$17.8 million for Q1 2026 at Lyell Immunopharma, down from $82.3 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $104.7 million in Q4 2022 to a low of -$45.7 million in Q1 2022.
- A 5-year average of -$4.7 million and a median of -$36.7 million in 2024 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments declined 18.66% in 2024 and jumped 45.69% in 2025, its largest moves.
- Lyell Immunopharma's Other Gross PP&E Adjustments stood at $104.7 million in 2022, then slipped by 1.24% to $103.4 million in 2023, then slipped by 18.66% to $84.1 million in 2024, then decreased by 2.16% to $82.3 million in 2025, then sank by 121.67% to -$17.8 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$17.8 million, $82.3 million, and -$19.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -17.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.83 Mn |
| Mar 31, 2026 | -17.83 Mn |
| Dec 31, 2025 | 82.29 Mn |
| Dec 31, 2025 | 82.29 Mn |
| Sep 30, 2025 | -19.91 Mn |
| Sep 30, 2025 | -19.91 Mn |
| Jun 30, 2025 | -20.95 Mn |
| Jun 30, 2025 | -20.95 Mn |
| Mar 31, 2025 | -23.57 Mn |
| Mar 31, 2025 | -23.57 Mn |
| Dec 31, 2024 | 84.10 Mn |
| Dec 31, 2024 | 84.10 Mn |
| Sep 30, 2024 | -36.66 Mn |
| Sep 30, 2024 | -36.66 Mn |
| Jun 30, 2024 | -37.70 Mn |
| Jun 30, 2024 | -37.70 Mn |
| Mar 31, 2024 | -38.70 Mn |
| Mar 31, 2024 | -38.70 Mn |
| Dec 31, 2023 | 103.39 Mn |
| Dec 31, 2023 | 103.39 Mn |
| Sep 30, 2023 | -40.60 Mn |
| Sep 30, 2023 | -40.60 Mn |
| Jun 30, 2023 | -41.51 Mn |
| Jun 30, 2023 | -41.51 Mn |
| Mar 31, 2023 | -42.39 Mn |
| Mar 31, 2023 | -42.39 Mn |
| Dec 31, 2022 | 104.69 Mn |
| Dec 31, 2022 | 104.69 Mn |
| Sep 30, 2022 | -44.08 Mn |
| Sep 30, 2022 | -44.08 Mn |
| Jun 30, 2022 | -44.91 Mn |
| Jun 30, 2022 | -44.91 Mn |
| Mar 31, 2022 | -45.73 Mn |
| Mar 31, 2022 | -45.73 Mn |
| Dec 31, 2021 | 85.20 Mn |
| Dec 31, 2021 | 85.20 Mn |
| Sep 30, 2021 | -47.24 Mn |
| Sep 30, 2021 | -47.24 Mn |
| Jun 30, 2021 | -48.42 Mn |
| Jun 30, 2021 | -48.42 Mn |
| Dec 31, 2020 | 29.96 Mn |
| Dec 31, 2020 | 29.96 Mn |